Based on the typical drug development timeline, Eli Lilly (the manufacturer) is expected to file a New Drug Application (NDA) in late 2026, with potential FDA approval in 2027 if the review process goes smoothly
Reduced procedural complexity compared to intravenous delivery
The challenge is that GLP-1 and GIP are structurally similar but not identical
Ozempic , Mounjaro ) with only modest results
Both drugs are weekly injections that assist with weight loss and are indicated for individuals with elevated BMI or health complications
This variant incorporates an 18-carbon hydrophobic fatty acid side chain (1,18-octadecanedioic acid) to bind the peptide to albumin, which is akin to attaching a house to GLP-1, says chemist Krishna Kumar from Tufts University in Massachusetts, US